Supernus Pharmaceuticals, Inc. (SUPN) NASDAQ

Currency In USD

AD

Valuation

Market Cap2.81B
Enterprise Value2.72B
P/E Ratio-21.95
PEG Ratio0.21
Price/Sales Ratio2.95
Price/Book Ratio2.38
Enterprise/Revenue2.78
Enterprise/EBITDA-145.47

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterJune 30, 2026

Profitability

Profit Margin-0.13
Operating Margin-0.13
AD

Management Effectiveness

Return On Assets-0.08
Return On Equity-0.1

Income Statement

Revenue718.95M
Revenue/Share14.3
Gross Profit644.39M
EBITDA42.53M
Net Income-38.55M
Diluted EPS-0.68

Balance Sheet

Total Cash372.07M
Total Cash/Share6.41
Total Debt40.17M
Total Debt/Equity0.04
Current Ratio2.08
Book Value Per Share17.76

Price History

52-Week Change-12.2
52-Week High59.68
52-Week Low40.51
Moving Average 50 Days44.92
Moving Average 200 Days48.26

Statistics

Average Volume786,863
Shares Outstanding58.04M
% Held by Institutions105.03

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split FactorN/A
Last Split DateN/A
AD